Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 4, 2008, Pages 797-808

  Duvivier, Claudine ^a,b,c,e,g,h   Ghosn, Jade ^a,c,g,i   Assoumou, Lambert ^b,c   Soulié, Cathia ^a,b   Peytavin, Gilles ^d   Calvez, Vincent ^a,b   Génin, Michèle Algarté ^b,c   Molina, Jean Michel ^a,e   Bouchaud, Olivier ^a,f   Katlama, Christine ^a,b,c   Costagliola, Dominique ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITÉ PARIS 13   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h INSTITUT PASTEUR   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Antiretroviral efficacy; HIV 1; Lipoatrophy syndrome; NRTI sparing regimen; Tolerance

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AFRICA; ANEMIA; ANTIVIRAL RESISTANCE; ARTICLE; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VIRUS MUTATION;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 53049083334     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn278     Document Type: Article

References (52)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863-8.
3. EI-Sadr WM, Lundgren JD, Neaton JD et al. CD4+ count-guided interruption of antiretrovirall treatment. N Engl J Med 2006; 355: 2283-96.
4. Bemasconi E, Boubaker K, Junghans C et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31: 50-5.
5. Mallal SA, John M, Moore CB et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-16.
6. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
7. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005; 10 Suppl 2: M47-52.
8. Smith DE, Carr A, Law M et al. Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: The PIILR extension study. AIDS 2002; 16: 2489-91.
9. McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-70.
10. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. J Am Med Assoc 2002; 288: 207-15.
11. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
12. Murphy R, Zhang J, Hafner R et al. and AACTG 5110 Study Team. Switching to a thymidine analog-sparing or a nucleoside-sparing regimen improves lipoatrophy: 24-week results of a prospective randomized clinical trial, AACTG 5110. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, 2005. http://www.retroconference.org/ 2005/cd/Abstracts/25715.htm (31 May 2008, date last accessed).
13. Allavena C, Ferre V, Brunet-Francois C et al. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39: 300-6.
14. Valantin MA, Lanoy E, Bentata M et al. and the NONUKE ANRS 108 study team. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96 week randomized ANRS 108 NONUKE trial. HIV Med 2008; in press.
15. Ward D, Bush L, Thiry A et al. Atazanavir/ritonavir (ATV/r) and efavirenz (EFV) NRTI-sparing regimens in treatment-naïve adults: BMS -121 Study. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract H-1057. American Society for Microbiology, Washington, DC, USA.
16. Fischl MA, Collier AC, Mukherjee AL et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS 2007; 21: 325-33.
17. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 2003; 63: 769-802.
18. Lal R, Hsu A, Granneman GR et al. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, 1998. http://www.retroconference.org/1998/ Abstracts/647.htm (31 May 2008, date last accessed).
19. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. J Am Med Assoc 2006; 296: 827-43.
20. Carrieri P, Cailleton V, Le Moing V et al. The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001; 28: 232-9.
21. Duran S, Saves M, Spire B et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001; 15: 2441-4.
22. Sham HL, Kempf DJ, Molla A et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218-24.
23. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH: Rapport 2000. Médecine-Sciences Flammarion, Paris, 2000.
24. Burger DM, Hoetelmans RM, Hugen PW et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3: 215-20.
25. Acosta EP, Henry K, Baken L et al. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708-12.
26. Ghosn J, Lamotte C, Ait-Mohand H et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17: 209-14.
27. van Heeswijk RP, Veldkamp AI, Mulder JW et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14: F77-82.
28. Havlir D, Cheeseman SH, McLaughlin M et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-45.
29. Veldkamp AI, Weverling GJ, Lange JM et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15: 1089-95.
30. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I et al. Liver toxicity caused by nevirapine. AIDS 2002; 16: 290-1.
31. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 2004; 18: 1029-36.
32. Moyle GJ, Baldwin C, Langroudi B et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 22-8.
33. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. J Am Med Assoc 2004; 292 191-201.
34. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
35. Cassetti I, Madruga JV, Suleiman JM et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8: 164-72.
36. Haubrich RH, Riddler S, DiRienzo G et al. and the ACTG 5142 Study Team. Metabolic outcomes of ACTG 5142: A prospective, randomized, Phase III trial of NRTI-, PI-, NNRTI-sparing regimens for initial treatment of HIV-1 infection. Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 32. http://www.retroconference.org/2007/Abstracts/29065.htm (31 May 2008, date last accessed).
37. Bartlett JA, Fath W, Demasi R et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20: 2051-64.
38. Gulick RM, Ribaudo HJ, Shikuma CM et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850-61.
39. Poznlak AL, Gallant JE, Dejesus E et al. Superior outcome for tenofovir DF, emtricitabine and efavirenz compared to fixed dose zidovudine/lamivudine and EFV in antiretroviral naive patients. Third IAS Conference on HIV Pathogenesis and Treatment, Rio do Janeiro, Brasil, 2005. Abstract We.OA 02.02. http://www.iasociety.org/ Default.aspx?pageId=11&abstractId=2176862 (31 May 2008, date last accessed).
40. Riddler SA, Haubrich R, DiRienzo G et al., for the AIDS Clinical Trials Group study A5142 team. Class-sparing regimes for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106.
41. Gulick RM, Ribaudo HJ, Shikuma CM et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. J Am Med Assoc 2006; 296: 769-81.
42. Bartlett JA, Buda JJ, von Scheele B et al. Minimizing resistance consequences after virologic failure on initial combination therapy: A systematic overview. J Acquir Immune Defic Syndr 2006; 41: 323-31.
43. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16: 1139-46.
44. Neilen JF, Wit FW, De Wolf F et al. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and non-indigenous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr 2004; 36: 943-50.
45. van den Berg JB, Hak E, Vervoort SC et al. Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy. HIV Med 2005; 6 299-306.
46. Schackman BR, Ribaudo HJ, Krambrink A et al. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing: Results of ACTG A5095. J Acquir Immune Defic Syndr 2007; 46: 547-54.
47. Wang J, Sönnerborg A, Rane A et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16: 191-8.
48. Wyen C, Hendra H, Vogel M et al., German Competence Network for HIV/AIDS. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61: 914-8.
49. Breton G, Lewden C, Spire B et al. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France. HIV Med 2007; 8: 164-70.
50. Mills EJ, Nachega JB, Buchan I et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. J Am Med Assoc 2006; 296: 679-90.
51. Egger M. Outcomes of ART in resource-limited and industrialized countries. 14th Conference on Retroviruses and Opportunistic InfeWtions, Los Angeles, CA, 2007. Paper #: 62. http://www.retroconference.org/2007/Abstracts/30600.htm (31 May 2008, date last accessed).
52. Bangsberg DR, Hecht FM, Charlebois ED et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-66.